Insider Buying: Anixa Biosciences, Inc. (NASDAQ:ANIX) CFO Buys $19,971.35 in Stock

Anixa Biosciences, Inc. (NASDAQ:ANIX) CFO Michael Catelani acquired 9,289 shares of the company’s stock in a transaction that occurred on Wednesday, January 15th. The shares were bought at an average price of $2.15 per share, with a total value of $19,971.35. Following the transaction, the chief financial officer now owns 44,500 shares in the company, valued at $95,675. This represents a 26.38 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Anixa Biosciences Trading Down 6.6 %

Shares of NASDAQ:ANIX opened at $2.41 on Friday. The firm has a market cap of $77.59 million, a price-to-earnings ratio of -6.18 and a beta of 0.90. The stock’s 50-day moving average price is $2.80 and its two-hundred day moving average price is $3.02. Anixa Biosciences, Inc. has a 12-month low of $2.07 and a 12-month high of $5.13.

Anixa Biosciences (NASDAQ:ANIX) last released its earnings results on Friday, January 10th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.11) by $0.02. As a group, research analysts forecast that Anixa Biosciences, Inc. will post -0.46 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on ANIX shares. HC Wainwright reiterated a “buy” rating and set a $7.00 price target on shares of Anixa Biosciences in a report on Tuesday, November 19th. D. Boral Capital reaffirmed a “buy” rating and issued a $10.00 target price on shares of Anixa Biosciences in a research note on Tuesday.

Institutional Trading of Anixa Biosciences

Several institutional investors have recently made changes to their positions in ANIX. Virtu Financial LLC acquired a new stake in Anixa Biosciences during the third quarter worth about $34,000. Concorde Asset Management LLC purchased a new stake in shares of Anixa Biosciences during the 2nd quarter worth about $31,000. Westside Investment Management Inc. grew its holdings in shares of Anixa Biosciences by 151.8% during the 3rd quarter. Westside Investment Management Inc. now owns 35,000 shares of the company’s stock worth $110,000 after purchasing an additional 21,100 shares during the period. International Assets Investment Management LLC increased its position in Anixa Biosciences by 170.0% during the 3rd quarter. International Assets Investment Management LLC now owns 37,800 shares of the company’s stock worth $1,190,000 after purchasing an additional 23,800 shares in the last quarter. Finally, Tyler Stone Wealth Management raised its holdings in Anixa Biosciences by 100.0% in the third quarter. Tyler Stone Wealth Management now owns 42,016 shares of the company’s stock valued at $132,000 after buying an additional 21,008 shares during the period. 29.13% of the stock is owned by hedge funds and other institutional investors.

Anixa Biosciences Company Profile

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.